| Title | The use of sibutramine in the management of obesity and related disorders: an update. | | Author(s) | Tziomalos K, Krassas GE, Tzotzas T | | Institution | Department of endocrinology, Diabetes and Metabolism, Panagia General Hospital, Thessaloniki, Greece. | | Source | Vasc Health Risk Manag 2009; 5(1):441-52. | | MeSH | Adult
Appetite Depressants
Biological Markers
Blood Glucose
Cardiovascular Diseases
Child
Cyclobutanes
Eating
Humans
Inflammation Mediators
Lipids
Obesity
Risk Reduction Behavior
Treatment Outcome
Weight Loss
| | Abstract | AIMS: To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders.
METHODS AND RESULTS: The most important articles on sibutramine up to January 2009 were located by a PubMed and Medline search. Sibutramine reduces food intake and body weight more than placebo and has positive effects on the lipid profile (mainly triglycerides and high density lipoprotein cholesterol), glycemic control and inflammatory markers in studies for up to one year. Preliminary studies showed that sibutramine may also improve other obesity-associated disorders such as polycystic ovary syndrome, left ventricular hypertrophy, binge eating disorder and adolescent obesity. The high discontinuation rates and some safety issues mainly due to the increase in blood pressure and pulse rate have to be considered. Additionally, it has not yet been established that treatment with sibutramine will reduce cardiovascular events and total mortality.
CONCLUSIONS: Sibutramine, in conjunction with lifestyle measures, is a useful drug for reducing body weight and improving associated cardiometabolic risk factors and obesity-related disorders. Studies of longer duration are required to determine the precise indications of the drug, to evaluate safety issues and to assess its efficacy on cardiovascular mortality. | | Language | eng | | Pub Type(s) | Journal Article
Review
| | PubMed ID | 19475780 |
|
